Nader Francois 4

What Happened

• Nader Francois, a Moderna (MRNA) director, received equity awards on May 6, 2026 totaling 10,639 shares. The Form 4 reports two awards: a derivative award of 6,454 shares (option-style grant) and 4,185 restricted stock units (RSUs). Both awards were reported with a $0 acquisition price on the Form 4 (standard for grant reports); no cash was paid and no shares were sold.

Key Details

• Transaction date: May 6, 2026; Form 4 filed May 8, 2026 (timely filing).
• Awards: 6,454-share derivative grant (option-style) and 4,185 RSUs (total 10,639 shares).
• Reported acquisition price: $0.00 (award/grant — no immediate cash outlay or sale).
• Vesting/exercise: Option award becomes fully vested and exercisable on the earlier of May 6, 2027 or Moderna’s next Annual Meeting, subject to continued service (Footnote F1). The RSUs convert one-for-one to common stock and vest in full on the same schedule (Footnotes F2, F3).
• Shares owned after transaction: Not specified in the provided filing.
• Filing timeliness: Reported within two days of the transaction — not indicated as late.

Context

• These were grants/awards, not open-market purchases or sales, so they do not represent an immediate cash-in or cash-out by the insider. Options give the right to buy shares later (subject to vesting and exercise), while RSUs convert to actual shares when vested. Grants to directors are commonly part of compensation and subject to service-based vesting.